---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-151963"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:07:43.645093+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CFO Edward J. Dulac III resigns; CEO J. Scott Wolchko to assume CFO role effective June 14, 2024

## Summary
- Edward J. Dulac III resigned as CFO voluntarily, effective June 14, 2024; no disagreement with the company.
- CEO J. Scott Wolchko will succeed Dulac as CFO and principal financial/accounting officer immediately after resignation.
- Wolchko previously served as CFO from company inception until August 2020.

## SEC filing metadata
- accession: 0001193125-24-151963
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/d845254d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-151963
- JSON: https://secwatch.observer/filing/0001193125-24-151963.json
- Plain text: https://secwatch.observer/filing/0001193125-24-151963.txt

## Key facts
- Executive change
  J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: The Company’s board of directors intends to appoint J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Mr. Dulac as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm
- Executive change
  Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the “Company”), which will be effective June 14, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.